Vnda), a leading biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced positive topline. Key regulatory milestones include bysanti™ nda. A detailed overview of vanda pharmaceuticals inc
Wanda Nara suffers nip slip live on Instagram - but doesn't notice for
Engages in the development and commercialization of therapies for high unmet medical needs
The firm intends to treat schizophrenia, jet lag disorder, atopic.
Phase 3 anticipated in h1 2026. Vnda) today announced financial and operational results for the fourth quarter and full year ended december. Fanapt® showed strong performance with net sales of $29.3 million, up 27% yoy, while hetlioz® and ponvory® sales declined The company reported a net loss of $27.2 million for q2 2025
